MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.510
-0.170
-3.63%
Pre Market: 4.380 -0.13 -2.88% 07:15 03/04 EST
OPEN
4.680
PREV CLOSE
4.680
HIGH
4.787
LOW
4.480
VOLUME
1.71K
TURNOVER
--
52 WEEK HIGH
9.00
52 WEEK LOW
2.550
MARKET CAP
132.77M
P/E (TTM)
-2.1709
1D
5D
1M
3M
1Y
5Y
4 Penny Stocks to Watch in March If You Like Biotech, Are They A Buy?
Mar 02, 2021 (Penny Stocks via COMTEX) -- Will March be the Month That These Biotech Penny Stocks Jump? Over the past year, the attention paid to biotech...
Penny Stocks · 1d ago
Fragile X Syndrome Market 2021 Strategic Plans by Globally Industry Demand, On Going Trends, Regional Overview, Top Manufacture, Business Growth and Forecast to 2027, Says Industry Research Biz
The Express Wire · 2d ago
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
Zacks.com · 5d ago
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
Zacks · 5d ago
Hot Penny Stocks to Watch Today If You Like Marijuana Stocks
Feb 24, 2021 (Penny Stocks via COMTEX) -- Marijuana Stocks Are Heating Up The Stock Market Today We know the exotic nature of certain industries, especially...
Penny Stocks · 02/24 21:10
Global Fibromyalgia Therapeutics Drugs Market 2020 Trend and Opportunities, PESTEL Analysis, CAGR and Value Chain Study to 2025
Feb 22, 2021 (CDN Newswire via Comtex) -- Global Fibromyalgia Therapeutics Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to...
CDN Newswire · 02/23 01:43
Global Fibromyalgia Therapeutics Market 2020 Product Type, Applications, Market Share and Forecast by 2025
Feb 22, 2021 (CDN Newswire via Comtex) -- Global Fibromyalgia Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025 brings...
CDN Newswire · 02/23 01:41
Global Fibromyalgia Treatment Drug Market 2020 Technological Innovations, In-depth Qualitative Assessment and Industry Value Chain to 2025
Feb 22, 2021 (CDN Newswire via Comtex) -- Global Fibromyalgia Treatment Drug Market 2020 by Company, Regions, Type and Application, Forecast to 2025 aims to...
CDN Newswire · 02/23 01:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYNE. Analyze the recent business situations of Zynerba Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYNE stock price target is 7.25 with a high estimate of 9.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 6.74M
% Owned: 22.90%
Shares Outstanding: 29.44M
TypeInstitutionsShares
Increased
20
1.92M
New
23
-640.98K
Decreased
13
277.62K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Chief Executive Officer/Director
Armando Anido
President
Terri Sebree
Chief Financial Officer/Vice President
James Fickenscher
Vice President/General Counsel/Secretary
Suzanne Hanlon
Vice President
Brian Rosenberger
Vice President/Director of Investor Relations
William Roberts
Lead Director/Independent Director
Warren Cooper
Independent Director
John Butler
Independent Director
William Federici
Other
Liza Squires
Independent Director
Daniel Kisner
Independent Director
Kenneth Moch
Independent Director
Pamela Stephenson
No Data
About ZYNE
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.